<DOC>
	<DOCNO>NCT01383447</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose entinostat give together imatinib mesylate see well work treat patient relapsed refractory Philadelphia chromosome-positive acute lymphoblastic leukemia . Entinostat imatinib mesylate may stop growth cancer cell block enzymes need cell growth</brief_summary>
	<brief_title>Entinostat And Imatinib Mesylate In Treating Patients With Relapsed Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) entinostat give combination imatinib ( matinib mesylate ) . SECONDARY OBJECTIVES : I . To estimate rate complete response ( CR ) patient great ≥ 18 year age relapsed/refractory Ph+ ALL treat combination entinostat imatinib . II . To estimate 1 year progression free survival ( PFS ) patient great ≥ 18 year age relapsed/refractory Ph+ ALL treat combination entinostat imatinib III . To describe comparative pharmacokinetics ( PK ) pharmacodynamics ( PD ) entinostat administer alone vs. combination imatinib . IV . To assess predictive value level flow cytometric minimal residual disease ( MRD ) duration progression free survival study population . OUTLINE : This phase I , dose-escalation study entinostat follow phase II study . Patients receive entinostat orally ( PO ) daily day 1 , 8 , 15 , 22 imatinib mesylate PO twice daily day 1-28 ( day 4-28 course 1 ) . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients must histologically confirm BCRABL1 associate ( Ph+ ) acute lymphoblastic leukemia ( ALL ) primary refractory relapse disease ; demonstration BCRABL1 leukemia cell one follow require : ( 9 ; 22 ) ( q34 ; q11.2 ) cytogenetics ; FISH BCRABL1 fusion ; RTPCR BCRABL1 fusion Prior treatment tyrosine kinase inhibitor ( include imatinib , nilotinib and/or dasatinib ) allow , although patient must tyrosine kinase inhibitor minimum 72 hour prior begin protocol therapy ECOG performance status 0 , 1 2 Total WBC = &lt; 150,000 evidence ongoing impend leukostasis Total bilirubin = &lt; 2.0 mg/dL unless elevate due Gilbert 's , hemolysis leukemic infiltration Aspartate transaminase ( AST ) /alanine transaminase ( ALT ) = &lt; 2.5 × upper limit normal ( ULN ) unless due leukemic infiltration Serum creatinine = &lt; 2.0 mg/dL creatinine clearance &gt; 50 ml/min Left ventricular ejection fraction ( LVEF ) &gt; = 45 % measure echocardiogram ( ECHO ) MUGA Patients undergone stem cell transplantation ( SCT ) , autologous allogeneic , eligible provide &gt; 4 week stem cell infusion , active GVHD , meet eligibility criterion Patients fail primary induction therapy relapse achieve complete remission ( CR ) eligible &gt; 3 week cytotoxic chemotherapy &gt; 2 week radiation therapy ; patient must biologic therapy include hematopoietic growth factor &gt; 1 week ; use hydroxyurea ( HU ) , steroid , noncytotoxics blast count control , patient must &gt; 24 hr start protocol therapy ; patient must recover acute toxicity previous therapy Female patient childbearing age must negative pregnancy test ; woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign write informed consent document Patients may receive investigational agent Active CNS leukemia ; patient know previous CNS leukemia may continue receive intrathecal therapy araC , methotrexate , and/or thiotepa plus steroid prophylaxis reactivation previous CNS disease Patients may receive previous treatment entinostat HDAC inhibitor History allergic reaction attribute compound similar chemical biologic composition entinostat agent use study Uncontrolled intercurrent illness include , limited , ongoing active untreated infection , symptomatic congestive heart failure , unstable angina pectoris , unstable cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue mother treated entinostat HIVpositive patient combination antiretroviral therapy ineligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>